Endo Health Solutions (ENDP
) subsidiary Endo Pharmaceuticals says it's returning the global rights
for Urocidin to Bioniche Life Sciences. In November, Phase III clinical trials using Urocidin to treat non-muscle-invasive bladder cancer were discontinued because the trial was not recruiting at the expected rate and FDA officials had issues regarding the trials design, Endo decided to end the trial before its scheduled completion. In exchange for the return of the rights, Endo will receive a royalty on future revenue.